Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
Britannia Pharmaceuticals Ltd (United Kingdom)
Homepage:
britannia-pharm.co.uk
Alternate names:
Britannia Pharmaceuticals Limited,
Britannia Pharmaceuticals Ltd,
UK Britannia Pharmaceuticals
ROR:
02tg6rx53
OpenAlex ID:
I4405269016
Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial
2018
·
Regina Katzenschlager
, Werner Poewe
, et al.
·
The Lancet Neurology
·
373
Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study
2021
·
Regina Katzenschlager
, Werner Poewe
, et al.
·
Parkinsonism & Related Disorders
·
94
PDF
Organogel‐Based Emulsion Systems, Micro‐Structural Features and Impact on In Vitro Digestion
2009
·
Nicola Duffy
, Han C. G. Blonk
, et al.
·
Journal of the American Oil Chemists Society
·
88
A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal☆
2008
·
E YU
, K MIOTTO
, et al.
·
Drug and Alcohol Dependence
·
71
Inhaled synthetic surfactant abolishes the early allergen-induced response in asthma
2003
·
K.S. Babu
, D.A. Woodcock
, et al.
·
European Respiratory Journal
·
71
PDF
Practical use of apomorphine infusion in Parkinson’s disease: lessons from the TOLEDO study and clinical experience
2023
·
Tove Henriksen
, Regina Katzenschlager
, et al.
·
Journal of Neural Transmission
·
31
PDF
Levodopa–Entacapone–Carbidopa Intrajejunal Infusion in Advanced Parkinson's Disease – Interim Analysis of the ELEGANCE Study
2025
·
Daniel Weiss
, Wolfgang H. Jost
, et al.
·
Movement Disorders Clinical Practice
·
30
The Use of Lofexidine by Drug Dependency Units in the United Kingdom
1999
·
Jacqueline S. Akhurst
·
European Addiction Research
·
29
Lofexidine in opiate withdrawal: a safety and usage survey
2000
·
Jacqueline S. Akhurst
·
Pharmacoepidemiology and Drug Safety
·
10
Licensed Subcutaneous Infusion Therapies in Advanced Parkinson’s Disease: An Indirect Treatment Comparison and Cost-Minimisation Analysis
2025
·
Marc Vérin
, Ángel Sesar
, et al.
·
Neurology and Therapy
·
8
PDF
A case series of rapid titration of subcutaneous apomorphine in Parkinson's disease
2016
·
Jane Price
, Anne Martin
, et al.
·
British Journal of Neuroscience Nursing
·
4
Letter to the Editor Regarding ‘Levodopa Intestinal Gel Infusion Therapies in Advanced Parkinson's Disease: A Swedish Study on Real-World Use and Costs’
2025
·
Niall Smith
·
Neurology and Therapy
·
1
PDF
A decade of patient-focused innovation in the delivery of apomorphine infusion to improve the treatment experience for people with Parkinson’s
2026
·
B. Amlani
, V. Correa-Gallego
·
Parkinsonism & Related Disorders
Practical tools to improve usability and treatment experience with levodopa–carbidopa–entacapone intestinal gel in advanced Parkinson’s disease
2026
·
B. Amlani
, V. Correa-Gallego
, et al.
·
Parkinsonism & Related Disorders
Correlation between patient and clinician perceptions of disease improvement with levodopa–entacapone–carbidopa intestinal gel (LECIG) – data from ELEGANCE
2026
·
V. Correa-Gallego
, B. Amlani
·
Parkinsonism & Related Disorders
Device-aided therapy in advanced Parkinson’s should support an active life: Spanish case study of levodopa–carbidopa–entacapone intestinal gel infusion
2026
·
Correa-Gallego
, B. Amlani
, et al.
·
Parkinsonism & Related Disorders
Designing patient-centric device-aided therapies for advanced Parkinson’s disease: development of levodopa–carbidopa–entacapone intestinal gel infusion
2026
·
V. Correa-Gallego
, B. Amlani
·
Parkinsonism & Related Disorders
The Klem ring: Enhancing the LECIGON® (levodopa–entacapone–carbidopa intestinal gel) delivery system for the treatment of advanced Parkinson’s
2026
·
N.E. Holm
, B. Amlani
, et al.
·
Parkinsonism & Related Disorders
APO-go® (apomorphine hydrochloride) delivery innovation: experiences of Dutch Parkinson’s patients switching from pre-filled syringes to cartridges
2026
·
B. Amlani
, S. Franke
, et al.
·
Parkinsonism & Related Disorders
EE694 The Cost-Effectiveness of Targeted-Release Form (TRF)-Budesonide for the Treatment of Adult Population With Immunoglobulin A Nephropathy (IgAN) in Greece
2025
·
Katerina Vellopoulou
, Stylianos Ravanidis
, et al.
·
Value in Health
Experience with levodopa–entacapone–carbidopa intestinal infusion in Germany – interim results from the ELEGANCE study
2025
·
W.H. Jost
, B. Amlani
·
Parkinsonism & Related Disorders
Understanding patient perceptions of treatment with levodopa–entacapone–carbidopa intestinal infusion – real world insights from the ELEGANCE study
2025
·
N. Smith
, B. Amlani
·
Parkinsonism & Related Disorders
EE119 Development of a De Novo Model to Assess the Cost-Effectiveness of a New Treatment Option for Patients With Primary Immunoglobulin a Nephropathy (IgAN)
2023
·
N. Davies
, O. Dickinson
, et al.
·
Value in Health
PDF
New research into infant colic
2002
·
Dipak Kanabar
, Paul Clayton
, et al.
·
British Journal of Midwifery
RIBAVIRIN
1987
·
MaxwellE.P. Noble
·
The Lancet
Show more works
View as search
Works count:
25
Citation count:
1,304
Year
Topic
Type